



For Immediate Release

LMA RAISES STAKE IN AUSTRALIAN DISTRIBUTOR FROM 30% TO 80%
Investment in line with LMA's strategy to strengthen direct distribution capabilities in key markets

Singapore, 7 February 2007 – Mainboard-listed LMA International NV ("LMA"), the global leader in the development and marketing of the LMA™ laryngeal mask airway range of supraglottic airway management devices, has acquired a further 50% in the equity of Australian distributor LMA Pacific Medical Pty Ltd ("LMA PacMed"), increasing its investment from 30% to 80% for a consideration of US\$9.7 million.

Based on the terms of the agreement, 60% of this consideration will be in cash and 40% in new LMA shares to be issued at S\$0.88 per share. LMA has an option to acquire the remaining 20% within five years.

LMA PacMed, a privately owned company based in Melbourne, Australia, is a distributor of LMA's products in Australia and New Zealand, and manages a sales network that distributes LMA's products in Korea and Taiwan.

LMA CEO Michael Ashton expressed his excitement in acquiring a major equity position in this successful distributor. "This transaction is in line with our strategy to increase the number of key markets where we will have a direct sales capability to not only provide an increase in sales but also serve as a platform for new product opportunities," he said.

He further welcomed the chance to work more closely with the LMA PacMed CEO William Crothers. "William has built an excellent business in Australia and will work with us to expand the LMA presence in the Asia Pacific region," he added.

This transaction is expected to have a positive (but not material) impact on earnings per share and a negative impact on the net asset value per share of LMA shares for the financial year ending 31 December 2007. None of the Directors or controlling shareholder has an interest, direct or indirect, in the transaction.

- Ends -

For media queries, please contact:

Gavin Anderson & Company, Tel: +65 6339 9110

Sharon Seetho, Tel: +65 9009 8495

About LMA

Incorporated in the Netherlands Antilles in 1998, LMA was listed on the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ laryngeal mask airway range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA-Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ laryngeal mask airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Bonn, Germany and San Diego, California. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.